Biotech News
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk
First RSV vaccine approved for adults aged 18-59 years at increased risk and for all adults 60 years and older in Japan
Open original release
Related news
No closely related headlines were available from the latest feed snapshot.
GSK plc
GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Recent company news
GSKGSK plc2026-06-12 02:09:41 EST
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
GSKGSK plc2026-06-09 02:03:19 EST
GSK enters agreement to acquire Nuvalent, Inc.
GSKGSK plc2026-05-28 12:42:45 EST
Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
GSKGSK plc2026-05-26 17:15:19 EST
GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA
Stock data
- Close
- —
- Market cap
- —
- Exchange
- NYSE
- Sector
- Biotechnology
- Location
- United States